Excerpt from the PDA/DHI book Contamination Control in Healthcare Product Manufacturing, Volume 5
As part of the environmental monitoring performance qualification (EMPQ), surface and active viable air samples are typically taken near the same locations as the nonviable particulate samples.
A common approach in establishing the monitoring sites includes obtaining a map of the room, gridding the room into equal sections, and using the risk assessment analysis results to choose the most appropriate locations to sample. The information obtained from the risk assessment is then used to plot out where in the grid the sample(s) should be taken. Samples should be collected at the sites identified to contain the highest risk of contamination.
Equipment surface monitoring sites should also be based on risk assessment and will change from company to company depending on the equipment and the products being manufactured (Sutton, 2009). Note that all risk assessment decisions should be documented.
Samples can be taken randomly within the grid section, at the same place each time within the grid section, evenly distributed within the grid sections, or the sample sites can be determined by risk assessment (Sandle, 2016). A documented risk assessment for the selection of the sample sites should be performed (PDA TR 13).
By using the risk assessment approach, one can base the samplesites on the following information:
Sample sizes should be sufficient to optimize detection of environmental monitoring contaminants (FDA, 2004). Figure 1 demonstrates a room layout grid, which defines the sample locations to bemonitored during an EMPQ.
Figure 1 Sample Site Planning for EMPQ
International Organization for Standardization (ISO) (2015) ISO 14644-1:2015(E) Cleanrooms and Associated Controlled Environments – Part 1: Classification of Air Cleanliness.
Parental Drug Association (PDA) (2014) PDA Technical Report No.13, Revised 2014: Fundamentals of an Environmental Monitoring Program. PDA, Bethesda, MD.
Food and Drug Administration (FDA) (2004) Guidance for Industry: Sterile Drug Products Produced by Aseptic Processing – Current Good Manufacturing Practice. Food and Drug Administration, Rockville, MD, USA.
Sandle, T. (2016) “ISO 14644 Parts 1 and 2 – The Revised Cleanroom Standard and Contamination Control.” In Madsen, R. and Moldenhauer, J. (eds.) Contamination Control in Healthcare Product Manufacturing PDA/DHI, pp. 3–32.
Sutton, S. (2009) Qualification of an Environmental Monitoring Program –
1 Selection/Justification of Sample Sites. PMF Newsletter August.
United States Pharmacopeia (USP) <1116> Microbiological Evaluation of Cleanrooms and Other Controlled Environments.
Edited by Russell Madsen, Jeanne Moldenhauer
Available as book and PDF Single user.